Meta-analysis showed that 18F-FDG PET/CT had a moderate accuracy for the early prediction for pCR (sensitivity 85%, specificity 79% and diagnostic odds ratio 21.8), especially in HER2 positive and triple negative breast cancer 16, 17. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.